FGF21 and metabolic dysfunction-associated steatohepatitis: Serum FGF21 levels are significantly increased in patients with hepatic steatosis and NASH in a manner that is dependent on the degree of steatosis (Yilmaz and Eren, 2012; Shen et al., 2012, 2013; Li et al., 2013; Liu et al., 2015).